Orbimed Advisors Sells Shares in Enliven Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: NASDAQ.COM
- Share Reduction Transaction: On June 15, 2026, Orbimed Advisors sold 281,408 shares of Enliven Therapeutics for nearly $13 million at an average price of $45.02 per share, representing 3.67% of its holdings, indicating ongoing portfolio management adjustments.
- Holding Status Change: Following this sale, Orbimed continues to hold 7,388,902 shares of Enliven, maintaining over 10% ownership, which reflects its sustained interest in the company's future despite the recent reduction.
- Market Reaction Analysis: The sale occurred shortly after Enliven announced promising Phase III data for a leukemia drug, which may lead the market to interpret Orbimed's actions as a sign of caution regarding the company's prospects, particularly given the lackluster stock market performance.
- Investor Caution: Orbimed's sale, given its insider status with over 10% ownership, raises investor concerns; while the reasons for selling can vary, it is essential to carefully assess Enliven's investment value, especially since it was not included in the latest list of top recommended stocks by analysts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELVN
Wall Street analysts forecast ELVN stock price to fall
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 48.600
Low
35.00
Averages
40.67
High
48.00
Current: 48.600
Low
35.00
Averages
40.67
High
48.00
About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Orbimed Advisors Reduces Stake in Enliven Therapeutics
- Sale Overview: Orbimed Advisors recently sold 281,408 shares of Enliven Therapeutics for approximately $12.67 million, representing 3.67% of its indirect holdings, indicating a strategic decision while maintaining a significant investment in the company.
- Holding Analysis: Post-transaction, Orbimed continues to hold 7,388,902 shares indirectly, suggesting a sustained commitment to Enliven despite the recent sale, which reflects confidence in the company's future prospects.
- Market Reaction and Impact: This sale occurred shortly after Enliven announced promising clinical trial data for a leukemia drug, potentially indicating Orbimed's assessment of a market peak, although it does not necessarily imply a negative outlook on the company's future.
- Investor Considerations: As a long-term investor holding over 10% of the company, Orbimed's sale raises market awareness, prompting investors to interpret this move cautiously, as it may be driven by liquidity needs or portfolio rebalancing rather than a negative view on Enliven's fundamentals.
See More
Orbimed Advisors Sells Shares in Enliven Therapeutics
- Share Reduction Transaction: On June 15, 2026, Orbimed Advisors sold 281,408 shares of Enliven Therapeutics for nearly $13 million at an average price of $45.02 per share, representing 3.67% of its holdings, indicating ongoing portfolio management adjustments.
- Holding Status Change: Following this sale, Orbimed continues to hold 7,388,902 shares of Enliven, maintaining over 10% ownership, which reflects its sustained interest in the company's future despite the recent reduction.
- Market Reaction Analysis: The sale occurred shortly after Enliven announced promising Phase III data for a leukemia drug, which may lead the market to interpret Orbimed's actions as a sign of caution regarding the company's prospects, particularly given the lackluster stock market performance.
- Investor Caution: Orbimed's sale, given its insider status with over 10% ownership, raises investor concerns; while the reasons for selling can vary, it is essential to carefully assess Enliven's investment value, especially since it was not included in the latest list of top recommended stocks by analysts.
See More
Enliven Therapeutics Closes $460 Million Upsized Public Offering
- Upsized Offering: Enliven Therapeutics successfully completed an upsized public offering of 10,533,334 shares, including the full exercise of a 1,600,000 share over-allotment option at a price of $37.50 per share, indicating strong market demand and providing substantial funding for the company.
- Significant Proceeds: The offering generated approximately $460 million in gross proceeds before deducting underwriting discounts and other expenses, which will be allocated towards the development of small molecule therapeutics, further advancing its clinical-stage projects.
- Strong Underwriter Lineup: The offering was managed by prominent financial institutions including Jefferies, Goldman Sachs, Morgan Stanley, and Barclays, enhancing market confidence in Enliven and laying a solid foundation for future capital market activities.
- Compliance and Transparency: The offering was conducted under a SEC registration statement, ensuring compliance and transparency, which bolsters investor trust in corporate governance and provides a solid legal framework for future financing activities.
See More
Enliven Therapeutics Closes $460 Million Upsized Public Offering
- Upsized Offering: Enliven Therapeutics successfully closed an upsized public offering of 10,533,334 shares, including the full exercise of a 1,600,000-share over-allotment option at a public price of $37.50 per share, indicating strong market demand for its small molecule therapeutics.
- Significant Proceeds: The offering generated approximately $460 million in gross proceeds before deducting underwriting discounts and other expenses, which will be utilized to support the company's clinical-stage biopharmaceutical development, enhancing its competitive position in the market.
- Strong Underwriting Team: The offering was managed by prominent financial institutions including Jefferies, Morgan Stanley, and Barclays, reflecting investor confidence in Enliven and its potential for future growth.
- Regulatory Compliance: The offering was conducted under an SEC registration statement, ensuring compliance and enhancing investor trust in the company's transparency and legality, which is beneficial for future capital market activities.
See More
Biotech Company Movements Analysis
- TherapeuticsMD Strategic Review: TherapeuticsMD (TXMD) saw its shares soar over 20% as the company evaluates various strategic alternatives including acquisitions and mergers, with Q1 net income reaching $103,000, a significant turnaround from a $636,000 loss last year, indicating potential for transformation.
- Sensei Biotherapeutics Clinical Progress: Sensei Biotherapeutics (SNSE) experienced a 20.48% stock increase driven by optimism surrounding its key clinical trial; the drug PIKTOR is currently in a Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027, which could present significant market opportunities.
- Shattuck Labs Crohn's Disease Trial: Shattuck Labs (STTK) shares rose 18% as its candidate SL-325 demonstrated safety in a Phase 1 trial, with plans to initiate a Phase 2 trial for Crohn's disease in Q3 2026, potentially opening new treatment avenues for the company.
- Alumis NDA Submission Progress: Alumis (ALMS) saw a 15.55% increase in stock price, with its lead drug Envudeucitinib undergoing a pivotal Phase 2b study for systemic lupus erythematosus, and an NDA submission expected in Q4 2026, marking a significant advancement in the treatment of immune-mediated diseases.
See More
Enliven Therapeutics Announces Key Trial Alignment and Public Offering
- Trial Progress: Enliven Therapeutics announced that its experimental drug ELVN-001 demonstrated significant efficacy in chronic myeloid leukemia patients, with 48% of patients in the 80 mg daily dose group achieving a major molecular response, indicating strong potential for treatment success and likely boosting the company's future market performance.
- FDA Alignment: The company successfully aligned with the U.S. Food and Drug Administration (FDA) on key elements of its planned late-stage trial, expected to commence in the second half of 2026, marking a significant advancement in the company's clinical development efforts.
- Capital Raising Initiative: Enliven announced the pricing of its upsized public offering, expected to raise approximately $400 million in gross proceeds, which will provide essential funding for its research projects and further propel the development of ELVN-001.
- Analyst Ratings Optimistic: According to Koyfin data, all 10 analysts covering ELVN stock rate it as a 'Buy', with a 12-month price target of $60.11, representing a potential upside of about 49% from the last closing price, reflecting strong market confidence in the company's future performance.
See More
Orbimed Advisors Reduces Stake in Enliven Therapeutics
- Sale Overview: Orbimed Advisors recently sold 281,408 shares of Enliven Therapeutics for approximately $12.67 million, representing 3.67% of its indirect holdings, indicating a strategic decision while maintaining a significant investment in the company.
- Holding Analysis: Post-transaction, Orbimed continues to hold 7,388,902 shares indirectly, suggesting a sustained commitment to Enliven despite the recent sale, which reflects confidence in the company's future prospects.
- Market Reaction and Impact: This sale occurred shortly after Enliven announced promising clinical trial data for a leukemia drug, potentially indicating Orbimed's assessment of a market peak, although it does not necessarily imply a negative outlook on the company's future.
- Investor Considerations: As a long-term investor holding over 10% of the company, Orbimed's sale raises market awareness, prompting investors to interpret this move cautiously, as it may be driven by liquidity needs or portfolio rebalancing rather than a negative view on Enliven's fundamentals.
See More
Orbimed Advisors Sells Shares in Enliven Therapeutics
- Share Reduction Transaction: On June 15, 2026, Orbimed Advisors sold 281,408 shares of Enliven Therapeutics for nearly $13 million at an average price of $45.02 per share, representing 3.67% of its holdings, indicating ongoing portfolio management adjustments.
- Holding Status Change: Following this sale, Orbimed continues to hold 7,388,902 shares of Enliven, maintaining over 10% ownership, which reflects its sustained interest in the company's future despite the recent reduction.
- Market Reaction Analysis: The sale occurred shortly after Enliven announced promising Phase III data for a leukemia drug, which may lead the market to interpret Orbimed's actions as a sign of caution regarding the company's prospects, particularly given the lackluster stock market performance.
- Investor Caution: Orbimed's sale, given its insider status with over 10% ownership, raises investor concerns; while the reasons for selling can vary, it is essential to carefully assess Enliven's investment value, especially since it was not included in the latest list of top recommended stocks by analysts.
See More
Enliven Therapeutics Closes $460 Million Upsized Public Offering
- Upsized Offering: Enliven Therapeutics successfully completed an upsized public offering of 10,533,334 shares, including the full exercise of a 1,600,000 share over-allotment option at a price of $37.50 per share, indicating strong market demand and providing substantial funding for the company.
- Significant Proceeds: The offering generated approximately $460 million in gross proceeds before deducting underwriting discounts and other expenses, which will be allocated towards the development of small molecule therapeutics, further advancing its clinical-stage projects.
- Strong Underwriter Lineup: The offering was managed by prominent financial institutions including Jefferies, Goldman Sachs, Morgan Stanley, and Barclays, enhancing market confidence in Enliven and laying a solid foundation for future capital market activities.
- Compliance and Transparency: The offering was conducted under a SEC registration statement, ensuring compliance and transparency, which bolsters investor trust in corporate governance and provides a solid legal framework for future financing activities.
See More
Enliven Therapeutics Closes $460 Million Upsized Public Offering
- Upsized Offering: Enliven Therapeutics successfully closed an upsized public offering of 10,533,334 shares, including the full exercise of a 1,600,000-share over-allotment option at a public price of $37.50 per share, indicating strong market demand for its small molecule therapeutics.
- Significant Proceeds: The offering generated approximately $460 million in gross proceeds before deducting underwriting discounts and other expenses, which will be utilized to support the company's clinical-stage biopharmaceutical development, enhancing its competitive position in the market.
- Strong Underwriting Team: The offering was managed by prominent financial institutions including Jefferies, Morgan Stanley, and Barclays, reflecting investor confidence in Enliven and its potential for future growth.
- Regulatory Compliance: The offering was conducted under an SEC registration statement, ensuring compliance and enhancing investor trust in the company's transparency and legality, which is beneficial for future capital market activities.
See More
Biotech Company Movements Analysis
- TherapeuticsMD Strategic Review: TherapeuticsMD (TXMD) saw its shares soar over 20% as the company evaluates various strategic alternatives including acquisitions and mergers, with Q1 net income reaching $103,000, a significant turnaround from a $636,000 loss last year, indicating potential for transformation.
- Sensei Biotherapeutics Clinical Progress: Sensei Biotherapeutics (SNSE) experienced a 20.48% stock increase driven by optimism surrounding its key clinical trial; the drug PIKTOR is currently in a Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027, which could present significant market opportunities.
- Shattuck Labs Crohn's Disease Trial: Shattuck Labs (STTK) shares rose 18% as its candidate SL-325 demonstrated safety in a Phase 1 trial, with plans to initiate a Phase 2 trial for Crohn's disease in Q3 2026, potentially opening new treatment avenues for the company.
- Alumis NDA Submission Progress: Alumis (ALMS) saw a 15.55% increase in stock price, with its lead drug Envudeucitinib undergoing a pivotal Phase 2b study for systemic lupus erythematosus, and an NDA submission expected in Q4 2026, marking a significant advancement in the treatment of immune-mediated diseases.
See More
Enliven Therapeutics Announces Key Trial Alignment and Public Offering
- Trial Progress: Enliven Therapeutics announced that its experimental drug ELVN-001 demonstrated significant efficacy in chronic myeloid leukemia patients, with 48% of patients in the 80 mg daily dose group achieving a major molecular response, indicating strong potential for treatment success and likely boosting the company's future market performance.
- FDA Alignment: The company successfully aligned with the U.S. Food and Drug Administration (FDA) on key elements of its planned late-stage trial, expected to commence in the second half of 2026, marking a significant advancement in the company's clinical development efforts.
- Capital Raising Initiative: Enliven announced the pricing of its upsized public offering, expected to raise approximately $400 million in gross proceeds, which will provide essential funding for its research projects and further propel the development of ELVN-001.
- Analyst Ratings Optimistic: According to Koyfin data, all 10 analysts covering ELVN stock rate it as a 'Buy', with a 12-month price target of $60.11, representing a potential upside of about 49% from the last closing price, reflecting strong market confidence in the company's future performance.
See More
